Sai Life Sciences Limited has announced its earnings conference call to discuss the third quarter financial results for FY26, scheduled for February 6, 2026. The pharmaceutical contract research and manufacturing organization informed stock exchanges about this investor meeting pursuant to regulatory requirements.

Conference Call Details

The earnings conference call will be held on Friday, February 6, 2026, at 4:00 PM IST, with a duration of one hour until 5:00 PM. The session will focus on discussing the company's unaudited financial results for the third quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature key senior management representatives who will lead the discussion on quarterly performance:

• Krishna Kanumuri - Managing Director & Chief Executive Officer
• Siva Chittor - Director and Chief Financial Officer

The call will begin with a brief management discussion on earnings performance, followed by an interactive Question & Answer session with analysts and institutional investors.

Access Information

Participants can join the conference call through multiple channels. The company has provided domestic dial-in numbers along with international toll-free options for global participants. International attendees can use toll-free numbers for USA (18667462133), UK (08081011573), Singapore (8001012045), and Hong Kong (800964448).

A pre-registration facility is available for participants who wish to dial in directly without waiting for operator assistance. The company has provided a specific registration link for this convenience feature.

Regulatory Compliance

The announcement was made on January 28, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Runa Karan signed the regulatory filing, ensuring proper disclosure to both BSE Limited (Scrip Code: 544306) and National Stock Exchange of India Limited (Scrip Symbol: SAILIFE).

Sai Life Sciences operates as a global Contract Research, Development, and Manufacturing Organization (CRDMO), partnering with pharmaceutical and biotech companies for drug discovery, development, and commercialization services. The company is headquartered in Hyderabad with integrated solutions spanning medicinal chemistry, process development, and clinical manufacturing.

Sai Life Sciences Limited has received warning letters from both BSE and NSE for failing to hold mandatory Stakeholders' Relationship Committee (SRC) meetings during the financial year 2024-25. The exchanges issued the warning letters on January 06, 2026 and January 07, 2026 respectively, highlighting non-compliance with regulatory requirements.

Regulatory Violation Details

The warning letters specifically address the company's non-compliance with Regulation 20(3A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates that the Stakeholders' Relationship Committee shall meet at least once in a financial year. Both exchanges observed that no SRC meeting was conducted during the financial year ended March 31, 2025.

Company's Clarification

Sai Life Sciences had previously addressed this matter when NSE raised a query on May 21, 2025. The company provided clarification explaining that its equity shares were listed on stock exchanges effective December 18, 2024. Due to the short duration between the listing date and the financial year closure (December 18, 2024 to March 31, 2025), there were no urgent agenda items requiring presentation to the SRC during this period.

The company emphasized that the absence of SRC meetings was due to the brief operational window following its recent listing, rather than any deliberate non-compliance with regulatory requirements.

Exchange Actions and Requirements

Both BSE and NSE have taken a serious view of this non-compliance and issued formal warnings to the company. The exchanges have mandated specific corrective actions:

• Dissemination of warning letters on all stock exchanges where the company is listed
• Presentation of warning letters before the Board of Directors
• Implementation of corrective measures to prevent future lapses
• Strict adherence to all applicable exchange circulars and communications

The exchanges have warned that any future deviations will be viewed with utmost seriousness and may attract appropriate regulatory action.

Impact Assessment

According to the company's disclosure under Regulation 30 of SEBI LODR, there is no material impact on the financial, operational, or other activities of the company resulting from these warning letters. The company has reaffirmed its commitment to maintaining the highest standards of corporate governance and regulatory compliance.

Sai Life Sciences has assured stakeholders of its continued commitment to comply with all applicable SEBI regulations and listing requirements going forward. The company's response demonstrates its proactive approach to addressing regulatory concerns while maintaining transparency with investors and regulatory authorities.